The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Letters: Biomarkers for Rheumatoid Arthritis

Letters: Biomarkers for Rheumatoid Arthritis

May 15, 2015 • By Ronald van Vollenhoven, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Biomarkers for RA

I read the article, “Finding Biomarkers in RA Remains Elusive Goal” (February 2015 The Rheumatologist), with great interest. The author correctly identifies the multi-biomarker disease activity assay (MBDA; Vectra DA) as a potential biomarker that identifies RA patients at risk for radiographic progression. The author names a study presented at the 2014 ACR/ARHP Annual Meeting supporting this. I would like to point out that data from the SWEFOT clinical trial that were published earlier in 2014 (and presented at the 2013 ACR/ARHP Annual Meeting) demonstrated this same property of the MBDA, with the added point that when measured prior to treatment start in early RA (with MTX) the MBDA could distinguish patients at very low risk vs. those at moderate risk, with greater accuracy than CRP, ESR or DAS28.1

You Might Also Like
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
  • Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
Explore This Issue
May 2015

Moreover, the article in The Rheumatologist discusses the possibility that a (set of) biomarker(s) could help steer therapy. At the 2014 ACR/ARHP Annual Meeting we did, in fact, present data suggesting that the change in MBDA during MTX treatment could predict whether the most effective subsequent therapy will be “triple therapy” (MTX + sulfasalazine + hydroxychloroquine) or MTX + anti-TNF.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Sincerely,
Ronald van Vollenhoven, MD, PhD, Professor and Chief, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, and Chief, Clinical Trials Unit, Department of Rheumatology, The Karolinska University Hospital, Stockholm, Sweden

References

  1. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: Results from the SWEFOT trial. Ann Rheum Dis. 2014 May 8; pii: annrheumdis-2013-204986.
  2. Hambardzumyan K, Bolce RJ, Saevarsdottir S, et al. In early rheumatoid arthritis patients with non-response to methotrexate monotherapy the change in multi-biomarker disease activity score is differentially associated with subsequent response to non-biological versus biological therapy. Arthritis Rheumatol (ACR/ARHP Annual Meeting Abstracts). 2014;66(suppl 10):Abstract 45617.

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarker, Rheumatoid arthritis, viewpointIssue: May 2015

You Might Also Like:
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
  • Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Biomarkers in Rheumatoid Arthritis Remain Elusive

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.